The N-type calcium channel is a novel target for treating alcohol use disorders

Channels

Volumn 3, Issue 2, 2009, Pages 77-81

  Newton, Philip M ^a   Messing, Robert O ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN FRANCISCO   (United States)

Author keywords

Addiction; Alcoholism; N type calcium channel; NP078585; Place preference; Therapeutics

Indexed keywords

ALCOHOL; AMLODIPINE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL N TYPE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DOPAMINE RECEPTOR STIMULATING AGENT; ENDOCANNABINOID; GABAPENTIN; GLUTAMATE RECEPTOR ANTAGONIST; ION CHANNEL; LAMOTRIGINE; NALTREXONE; NP 078585; OPIATE; SEROTONIN AGONIST; TOPIRAMATE; UNCLASSIFIED DRUG; YOHIMBINE;

ALCOHOLISM; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG INHIBITION; DRUG TARGETING; HUMAN; INTOXICATION; MOUSE; NERVE CELL; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRESYNAPTIC INHIBITION; RAT; RODENT;

MUS; RODENTIA;

EID: 67049108975     PISSN: 19336950     EISSN: 19336969     Source Type: Journal    
DOI: 10.4161/chan.3.2.8037     Document Type: Article

References (58)

1. 2+ channels in mammalian central neurons. Trends in Neurosciences 1995; 18:89-98.
2. Ghosh A, Greenberg ME. Calcium signaling in neurons: Molecular mechanisms and cellular consequences. Science 1995; 268:239-247
3. Ertel EA, Campbell KP, Harpold MM, Hofmann F, Mori Y, Perez-Reyes E, et al. Nomenclature of voltage-gated calcium channels. Neuron 2000; 25:533-535
4. 2+ channels: a functional patchwork. Trends Neurosci 2003; 26:683-687
5. 2+ channel currents to a mu opioid in isolectin B4-positive and -negative dorsal root ganglion neurons. J Pharmacol Exp Ther 2004; 311:939-947
6. Kitamura G, Ohta T, Kai T, Kon Y, Ito S. Inhibitory effects of opioids on voltage-dependent Ca(2+) channels and catecholamine secretion in cultured porcine adrenal chromaffin cells. Brain Res 2002; 942:11-22.
7. Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 1997; 78:43-50. (Pubitemid 27318909)
8. Momiyama T, Koga E. Dopamine D(2)-like receptors selectively block N-type Ca(2+) channels to reduce GABA release onto rat striatal cholinergic interneurones. J Physiol 2001; 533:479-492
9. Carter TJ, Mynlieff M. Gamma-aminobutyric acid type B receptors facilitate L-type and attenuate N-type Ca(2+) currents in isolated hippocampal neurons. J Neurosci Res 2004; 76:323-333
10. 2+ currents in rat hippocampal interneurones and their selective inhibition by activation of GABA(B) receptors. J Physiol 1996; 492:115-127
11. Manita S, Kawamura Y, Sato K, Inoue M, Kudo Y, Miyakawa H. Adenosine A(1)-receptor-mediated tonic inhibition of glutamate release at rat hippocampal CA3-CA1 synapses is primarily due to inhibition of N-type Ca(2+) channels. Eur J Pharmacol 2004; 499:265-274
12. Mailliard WS, Diamond I. Recent advances in the neurobiology of alcoholism: the role of adenosine. Pharmacol Ther 2004; 101:39-46. (Pubitemid 38068524)
13. Heilig M, Egli M. Pharmacological treatment of alcohol dependence: Target symptoms and target mechanisms. Pharmacol Ther 2006; 111:855-876 (Pubitemid 44118437)
14. Choi DS, Cascini MG, Mailliard W, Young H, Paredes P, McMahon T, et al. The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference. Nat Neurosci 2004; 7:855-861 (Pubitemid 38989509)
15. Currie KP, Fox AP. Comparison of N- and P/Q-type voltage-gated calcium channel current inhibition. J Neurosci 1997; 17:4570-4579 (Pubitemid 27246915)
16. Colecraft HM, Patil PG, Yue DT. Differential occurrence of reluctant openings in G-protein-inhibited N- and P/Q-type calcium channels. J Gen Physiol 2000; 115:175-192
17. Kenna GA, McGeary JE, Swift RM. Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1. Am J Health Syst Pharm 2004; 61:2272-2279
18. Kenna GA, McGeary JE, Swift RM. Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 2. Am J Health Syst Pharm 2004; 61:2380-2388 (Pubitemid 40403581)
19. Finney JW, Hahn AC, Moos RH. The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction 1996; 91:1773-1796 (Pubitemid 27032490)
20. Newton PM, Messing RO. Intracellular signaling pathways that regulate behavioral responses to ethanol. Pharmacol Ther 2006; 109:227-237 (Pubitemid 41740823)
21. Newton PM, Ron D. Protein Kinase C and Alcohol Addiction. Pharm Res 2007.
22. Vengeliene V, Bilbao A, Molander A, Spanagel R. Neuropharmacology of alcohol addiction. Br J Pharmacol 2008; 154:299-315.
23. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C, et al. Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 2008; 319:1536-1539
24. Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA 2007; 104:12518-12523 (Pubitemid 47206170)
25. Mann K, Kiefer F, Spanagel R, Littleton J. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 2008; 32:1105-1110
26. Spanagel R, Kiefer F. Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci 2008; 29:109-115
27. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295:2003-2017 (Pubitemid 44794003)
28. Book SW, Myrick H. Novel anticonvulsants in the treatment of alcoholism. Expert Opin Investig Drugs 2005; 14:371-376 (Pubitemid 40711848)
29. Kushner MG, Abrams K, Borchardt C. The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings. Clin Psychol Rev 2000; 20:149-171 (Pubitemid 30100430)
30. Brown SA, Vik PW, Patterson TL, Grant I, Schuckit MA. Stress, vulnerability and adult alcohol relapse. J Stud Alcohol 1995; 56:538-545
31. Cosci F, Schruers KR, Abrams K, Griez EJ. Alcohol use disorders and panic disorder: a review of the evidence of a direct relationship. J Clin Psychiatry 2007; 68:874-880 (Pubitemid 47015486)
32. Kiefer F, Jimenez-Arriero MA, Klein O, Diehl A, Rubio G. Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone. Addict Biol 2008; 13:124-129
33. Soyka M, Roesner S. New pharmacological approaches for the treatment of alcoholism. Expert Opin Pharmacother 2006; 7:2341-2353 (Pubitemid 44842917)
34. Brady KT, Lydiard RB. The association of alcoholism and anxiety. Psychiatr Q 1993; 64:135-149
35. McMahon T, Andersen R, Metten P, Crabbe JC, Messing RO. Protein kinase C epsilon mediates upregulation of N-type calcium channels by ethanol. Mol Pharm 2000; 57:53-58 (Pubitemid 30033259)
36. Newton PM, Tully K, McMahon T, Connolly J, Dadgar J, Treistman SN, et al. Chronic ethanol exposure induces an N-type calcium channel splice variant with altered channel kinetics. FEBS Lett 2005; 579:671-676
37. Newton PM, Orr CJ, Wallace MJ, Kim C, Shin HS, Messing RO. Deletion of N-type calcium channels alters ethanol reward and reduces ethanol consumption in mice. J Neurosci 2004; 24:9862-9869 (Pubitemid 39463566)
38. Newton P, Zeng L, Wang V, Connolly J, Wallace M, Kim C, et al. A Blocker of N- and T-type Voltage-Gated Calcium Channels Attenuates Ethanol-Induced Intoxication, Place Preference, Self-Administration and Relapse. J Neurosci 2008; 28:11712-11719
39. Egli M. Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism? Addict Biol 2005; 10:309-319
40. Le A, Shaham Y. Neurobiology of relapse to alcohol in rats. Pharmacol Ther 2002; 94:137-156 (Pubitemid 34615963)
41. Tzschentke TM. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 1998; 56:613-672 (Pubitemid 29012461)
42. Mathews IZ, McCormick CM. Female and male rats in late adolescence differ from adults in amphetamine-induced locomotor activity, but not in conditioned place preference for amphetamine. Behav Pharmacol 2007; 18:641-650 (Pubitemid 47524890)
43. Vazquez V, Weiss S, Giros B, Martres MP, Dauge V. Maternal deprivation and handling modify the effect of the dopamine D3 receptor agonist, BP 897 on morphine-conditioned place preference in rats. Psychopharmacology (Berl) 2007; 193:475-486
44. Walf AA, Rhodes ME, Meade JR, Harney JP, Frye CA. Estradiol-induced conditioned place preference may require actions at estrogen receptors in the nucleus accumbens. Neuropsychopharmacology 2007; 32:522-530 (Pubitemid 46271047)
45. Sellings LH, McQuade LE, Clarke PB. Characterization of dopamine-dependent rewarding and locomotor stimulant effects of intravenously-administered methylphenidate in rats. Neuroscience 2006; 141:1457-1468 (Pubitemid 44144510)
46. Cain SW, Ko CH, Chalmers JA, Ralph MR. Time of day modulation of conditioned place preference in rats depends on the strain of rat used. Neurobiol Learn Mem 2004; 81:217-220 (Pubitemid 38479662)
47. Bossert JM, Franklin KB. Pentobarbital-induced place preference in rats is blocked by GABA, dopamine and opioid antagonists. Psychopharmacology (Berl) 2001; 157:115-122 (Pubitemid 32802122)
48. Tzschentke TM. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 2007; 12:227-462. (Pubitemid 47196347)
49. Maldonado R. Study of cannabinoid dependence in animals. Pharmacol Ther 2002; 95:153-164 (Pubitemid 35232133)
50. Risinger FO, Cunningham CL, Bevins RA, Holloway FA. Place conditioning: what does it add to our understanding of ethanol reward? Alcohol Clin Exp Res 2002; 26:1444-1452
51. Williams ME, Brust PF, Feldman DH, Patthi S, Simerson S, Maroufi A, et al. Structure and functional expression of an ω-conotoxin-sensitive human N-type calcium channel. Science 1992; 257:389-395
52. McCleskey EW, Fox AP, Feldman DH, Cruz LJ, Olivera BM, Tsien RW, et al. Omega-conotoxin: direct and persistent blockade of specific types of calcium channels in neurons but not muscle. Proc Natl Acad Sci USA 1987; 84:4327-4331 (Pubitemid 17090927)
53. 2+ channel toxins in DBA/2 mice. Psychopharmacology 1996; 126:85-90.
54. Lynch SS, Cheng CM, Yee JL. Intrathecal ziconotide for refractory chronic pain. Ann Pharmacother 2006; 40:1293-1300 (Pubitemid 44204959)
55. Snutch TP. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx 2005; 2:662-670 (Pubitemid 41393273)
56. Siggins GR, Roberto M, Nie Z. The tipsy terminal: presynaptic effects of ethanol. Pharmacol Ther 2005; 107:80-98. (Pubitemid 40800409)
57. Poncer JC, McKinney RA, Gahwiler BH, Thompson SM. Differential control of GABA release at synapses from distinct interneurons in rat hippocampus. J Physiol 2000; 528:123-130
58. Tredway TL, Guo JZ, Chiappinelli VA. N-type voltage-dependent calcium channels mediate the nicotinic enhancement of GABA release in chick brain. J Neurophysiol 1999; 81:447-454 (Pubitemid 29264492)